Treatment-refractory schizophrenia in children and adolescents: An update on clozapine and other pharmacologic interventions

Child and Adolescent Psychiatric Clinics of North America

Volumn 15, Issue 1, 2006, Pages 135-159

  Kranzler, Harvey N ^a,b   Kester, Hana M ^c   Gerbino Rosen, Ginny ^a,b   Henderson, Inika N ^b   Youngerman, Joseph ^a,b   Beauzile, Guy ^d   Ditkowsky, Keith ^e   Kumra, Sanjiv ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Bronx Children's Psychiatric Center   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d Sagamore Children's Psychiat Center   (United States)

^e SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LIVER ENZYME; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGRANULOCYTOSIS; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; BLOOD DYSCRASIA; BLOOD TOXICITY; BRAIN DISEASE; BRAIN SIZE; CHILD PSYCHIATRY; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DELIRIUM; DELUSION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSKINESIA; ECG ABNORMALITY; EJACULATION DISORDER; ELECTROCONVULSIVE THERAPY; ENZYME BLOOD LEVEL; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HUMAN; HYPERGLYCEMIA; HYPERPHAGIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; INSULIN RESISTANCE; MENTAL CONCENTRATION; MENTAL PATIENT; META ANALYSIS; METABOLIC DISORDER; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NERVOUSNESS; NEUROANATOMY; NEUROTOXICITY; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; QT INTERVAL; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; CLOZAPINE; DRUG RESISTANCE; HUMANS; SCHIZOPHRENIA;

EID: 28444452918     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2005.08.008     Document Type: Review

References (165)

1. M. Krausz, and T. Müller-Thomsen Schizophrenia with onset in adolescence: an 11-year followup Schizophr Bull 19 4 1993 148 153
2. J. McClellan, and J. Werry Practice parameters for the assessment and treatment of children and adolescents with schizophrenia J Am Acad Child Adolesc Psychiatry 33 5 1994 616 635
3. J.H. Beitchman Childhood schizophrenia: a review and comparison with adult-onset schizophrenia Psychiatric Clin North Am 8 4 1985 793 798
4. K. McKenna, C.T. Gordon, and M. Lenane Looking for childhood-onset schizophrenia: the first 71 cases screened J Am Acad Child Adolesc Psychiatry 33 5 1994 636 644
5. C. Stayer, A. Sporn, and N. Gogtay Looking for childhood schizophrenia: case series of false positives J Am Acad Child Adolesc Psychiatry 43 2004 1026 1029
6. A.L. Sporn, A.M. Addington, and N. Gogtay Pervasive developmental disorder and childhood-onset schizophrenia: comorbid disorder or a phenotypic variant of a very early onset illness? Biol Psychiatry 55 2004 989 994
7. P.M. Thompson, C. Vidal, and J.N. Giedd Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia Proc Natl Acad Sci USA 98 2001 11650 11655
8. R.F. Asarnow, K.H. Neuchterlein, and K.L. Subotnik Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention-deficit/hyperactivity disorder: the University of California, Los Angeles Family Study Arch Gen Psychiatry 59 2002 1053 1060
9. P.A. Gochman, D. Greenstein, and A. Sporn Childhood onset schizophrenia: familial neurocognitive measures Schizophr Res 71 1 2004 43 47
10. A.M. Addington, M. Gornick, and J. Duckworth GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD(67)), is associated with childhood-onset schizophrenia and cortical gray matter volume loss Mol Psychiatry 10 6 2005 581 588
11. M. Maziade, N. Gingras, and C. Rodrigue Long-term stability of diagnosis and symptom dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence. I: nosology, sex and age of onset Br J Psychiatry 169 1996 361 370
12. C. Hollis Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity Am J Psychiatry 157 2000 1652 1659
13. J.S. Werry, J.M. McClellan, and L. Chard Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: a clinical and outcome study J Am Acad Child Adolesc Psychiatry 30 1991 457 465
14. A.T. Russell The clinical presentation of childhood-onset schizophrenia Schizophr Bull 20 1994 631 646
15. J.R. Asarnow Annotation: child-onset schizophrenia J Child Psychol Psychiatry 35 8 1994 1345 1371
16. M. Schmidt, B. Blanz, and A. Dippe Puberty and the onset of psychosis Schizophr Res 10 1 1995 7 14
17. C. Eggers Course and prognosis in childhood schizophrenia J Autism Child Schizophr 8 1978 21 36
18. C. Eggers, and D. Bunk The long-term course of childhood-onset schizophrenia: a 42-year follow up Schizophr Bull 23 1 1997 105 117
19. J.S. Werry, and J.M. McClellan Predicting outcome in child and adolescent (early onset) schizophrenia and bipolar disorder J Am Acad Child Adloesc Psychiatry 31 1 1992 147 150
20. G.P. Amminger, F. Resch, and R. Mutschlechner Premorbid adjustment and remission of positive symptoms in first-episode psychosis Eur Child Adolesc Psychiatry 6 4 1997 212 218
21. J. McClellan, A. Prezbindowski, and D. Breiger Neuropsychological functioning in early onset psychotic disorders Schizophr Res 68 2004 21 26
22. M. Oie, and B.R. Rund Neuropsychological deficits in adolescent-onset schizophrenia compared with attention deficit hyperactivity disorder Am J Psychiatry 156 1999 1216 1222
23. J. Rhinewine, T. Lencz, and E. Thaden Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates Biol Psychiatry 2005 Jul 13 [Epub ahead of print]
24. M.F. Green, R.S. Kern, and R.K. Heaton Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS Schizophr Res 71 1 2004 41 51
25. R.R. Conley, D.L. Kelly, and E.A. Gale Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse Schizophr Res 33 1998 95 101
26. Practice parameters for the assessment and treatment of children and adolescents with schizophrenia J Am Acad Child Adolesc Psychiatry 40 7 Suppl 2001 4S 23S
27. R.R. Conley, and R.W. Buchanan Evaluation of treatment-resistant schizophrenia Schizophr Bull 23 4 1997 663 674
28. D. Pool, W. Bloom, and D. Mielke A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients Curr Ther Res 19 1976 99 104
29. E.K. Spencer, V. Kafantaris, and M.V. Padron-Gayol Haloperidol in schizophrenic children: early findings from a study in progress Psychopharmacol Bull 28 1992 183 186
30. J.A. Lieberman, A.Z. Safferman, and S. Pollack Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome Am J Psychiatry 151 1994 1744 1752
31. H.Y. Meltzer, J. Rabinowitz, and M.A. Lee Age at onset and gender of schizophrenia patients in relation to neuroleptic resistance Am J Psychiatry 154 1997 475 482
32. H.Y. Meltzer Treatment of the neuroleptic nonresponsive schizophrenic patient Schizophr Bull 18 1992 515 542
33. A. Breier, R.W. Buchanan, and B. Kirkpatrick Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia Am J Psychiatry 151 1 1994 20 26
34. J.A. Lieberman, B.L. Saltz, and C.A. Johns The effects of clozapine on tardive dyskinesia Br J Psychiatry 158 1991 503 510
35. L. Sikich, R.M. Hamer, and R.A. Bashford A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial Neuropsychopharmacology 29 2004 133 145
36. S. Kumra, J.A. Frazier, and L.K. Jacobsen Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison Arch Gen Psychiatry 53 1996 1090 1097
37. M.G. Teicher, N.I. Barber, and H.A. Gelbard Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol Neuropsychopharmacology 9 2 1993 147 156
38. R. Lewis Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms Can J Psychiatry 43 1998 596 604
39. M. Mandoki Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 5 1995 49 67
40. M. Campbell, D. Grega, and W. Green Neuroleptic-induced dyskinesias in children Clin Neuropharmacol 6 1995 207 222
41. J. Claghorn, G. Honigfeld, and F.S. Abuzzahab Sr The risks and benefits of clozapine versus chlorpromazine J Clin Psychopharmacol 7 6 1987 377 384
42. J. Kane, G. Honigfeld, J. Singer Clozaril Collaborative Study Group Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine Arch Gen Psychiatry 45 1988 789 796
43. D.E. Casey Clozapine: neuroleptic-induced EPS and tardive dyskinesia Psychopharmacology (Berl) 99 Suppl 1989 S47 S53
44. J.M. Kane, M.G. Woerner, and S. Pollack Does clozapine cause tardive dyskinesia? J Clin Psychiatry 54 9 1993 327 330
45. D. Pickar, R.R. Owen, and R.E. Litman Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine Arch Gen Psychiatry 49 5 1992 345 353
46. J.M. Kane Tardive dyskinesia: epidemiological and clinical presentation E. Borroni D.J. Kupfer Psychopharmacology: the fourth generation of progress 1995 Raven Press New York 1485 1496
47. H.Y. Meltzer Clozapine: is another view valid? Am J Psychiatry 152 1995 821 825
48. L.H. Lindstrom The effect of long-term treatment with clozapine in schizophrenia Acta Psychiatr Scand 77 1988 524 529
49. L.H. Lindstrom Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs Acta Psychiatr Scand 89 1994 74 76
50. H.Y. Meltzer, L. Alphs, A.I. Green International Suicide Prevention Trial Study Group Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry 60 1 2003 82 91
51. M.J. Albanese, E.J. Khantzian, and S.L. Murphy Decreased substance use in chronically psychotic patients treated with clozapine Am J Psychiatry 151 5 1994 780 781
52. P. Buckley, P. Thompson, and L. Way Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy Am J Psychiatry 151 3 1994 385 389
53. P. Marcus, and R. Snyder Reduction of comorbid substance abuse with clozapine Am J Psychiatry 152 6 1995 959
54. S.M. Essock, W.A. Hargreaves, and F.A. Dohm Clozapine eligibility among state hospital patients Schizophr Bull 22 1 1996 15 25
55. Pollack S., Woerner M., Kane J. Clozapine reduces rehospitalization among schizophrenic patients. Poster presented at the 37th Annual Meeting of the New Clinical Drug Evaluation Unit Meeting. Boca Raton (FL), May 27-30, 1997
56. R.R. Conley, C.A. Tamminga, and D.L. Kelly Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response Biol Psychiatry 46 1999 73 77
57. K.E. Towbin, E.M. Dykens, and R.G. Pugliese Case study: clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome J Am Acad Child Adoles Psychiatry 33 1994 651 658
58. G. Siefen, and H. Remschmidt Treatment results with clozapine in schizophrenic adolescents Z Kinder Jugenpsychiatr 14 3 1986 245 257
59. H. Remschmidt, E. Schulz, and M. Martin An open trial of clozapine in thirty-six adolescents with schizophrenia J Child Adolesc Psychiatry 4 1994 31 41
60. M. Schmidt, G. Trott, and B. Blanz Clozapine medication in adolescents Psychiatry: a world perspective. Proceedings of the VIII World Congress of Psychiatry 1989 Elsevier Publishing Co. Amsterdam 1100 1104
61. T. Mozes, P. Toren, and N. Chernauzan Case study: clozapine treatment in very early onset schizophrenia J Am Acad Child Adolesc Psychiatry 33 1994 65 70
62. S.J. Grcevich, R.L. Findling, and W.A. Rowane Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study J Child Adolesc Psychopharmacol 6 4 1996 251 257
63. J.L. Armenteros, A.H. Whitaker, and M. Welikson Risperidone in adolescents with schizophrenia: an open pilot study J Am Acad Child Adolesc Psychiatry 36 5 1997 694 700
64. L.K. Jacobsen, M. Walker, and J. Edwards Clinical effects of clozapine in the treatment of a young adolescent with schizophrenia J Am Acad Child Adolesc Psychiatry 33 1994 645 660
65. C.U. Correll, S. Leucht, and J.M. Kane Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies Am J Psychiatry 161 3 2004 414 425
66. G. Gerbino-Rosen, D. Roofeh, and D.A. Tompkins Hematological adverse events in clozapine-treated children and adolescents J Am Acad Child Adolesc Psychiatry 44 10 2005 1024 1031
67. J.J. Ratey, C. Leveroni, and D. Kilmer The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital J Clin Psychiatry 54 6 1993 219 223
68. J. Volavka, J.M. Zito, and J. Vitrai Clozapine effects on hostility and aggression in schizophrenia J Can Psychopharmacol 13 4 1993 287 289
69. S.A. Cohen, and M.T. Underwood The use of clozapine in a mentally retarded and aggressive population J Clin Psychiatry 55 10 1994 440 444
70. S.B. Bellus, D. Stewart, and P.P. Kost Clozapine in aggression Psychiatr Serv 46 2 1995 187
71. H. Kranzler, D. Roofeh, and G. Gerbino-Rosen Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia J Am Acad Child Adolesc Psychiatry 44 1 2005 55 63
72. J.M. Alivir, and J.A. Lieberman Agranulocytosis: incidence and risk factors J Clin Psychiatry Suppl B 1994 137 138
73. G.E. Duncan, S. Miyamoto, and J.N. Leipzig Comparison of the effects of clozapine, risperidone and olanzapine on ketamine induced alterations in regional brain metabolism JPET 293 2000 8 14
74. C.M. Beasley Jr, G. Tollefson, P. Tran, Satterlee for the Olanzapine HGAD Study Group Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial Neuropsychopharmacology 14 1996 111 123
75. C.M. Beasley Jr, S.H. Hamilton, and A.M. Crawford Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial Eur Neuropsychopharmacol 7 2 1997 125 137
76. P.V. Tran, M.A. Dellva, and G.D. Tollefson Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia J Clin Psychiatry 58 5 1997 205 211
77. G.D. Tollefson, C.M. Beasley Jr, and P.V. Tran Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial Am J Psychiatry 154 4 1997 457 465
78. G.D. Tollefson, C.M. Beasley Jr, and R.N. Tamura Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol Am J Psychiatry 154 1997 1248 1254
79. W.M. Glazer Review of incidence studies of tardive dyskinesia associated with typical antipsychotics J Clin Psychiatry 61 Suppl 4 2000 15 20
80. C.M. Beasley Jr, T. Sanger, W. Satterlee for the Olanzapine HGAP Study Group Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial Psychopharmacology (Berl) 124 1996 159 167
81. G.D. Tollefson, and T.M. Sanger Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine Am J Psychiatry 154 4 1997 466 474
82. S.E. Purdon, B.D. Jones, and E. Stip Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. The Canadian Collaborative Group for research in schizophrenia Arch Gen Psychiatry 57 3 2000 249 258
83. B. Fulton, and K.L. Goa Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses Drugs 53 2 1997 281 298
84. A. Breier, and S.H. Hamilton Comparative efficacy of olanzapine and haloperidol for patients with treatment resistant schizophrenia Biol Psychiatry 45 4 1999 403 411
85. Beuzen J.N., Birkett M.A., Kiesler G.M., et al. Olanzapine vs. clozapine: an intermediate double-blind study in the treatment of resistant schizophrenia. Presented at the 39th Meeting of the New Clinical Drug Evaluation Unit. 1999
86. S.M. Dursun, D.M. Gardner, and D.C. Bird Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study Can J Psychiatry 44 1999 701 704
87. A. Fanous, and J.P. Lindenmayer Schizophrenia and schizoaffective disorder treated with high doses of olanzapine J Clin Psychopharmacol 19 1999 275 276
88. C.Q. Mountjoy, A.M. Baldacchino, and J.H. Stubbs British experience with high-dose olanzapine for treatment-refractory schizophrenia Am J Psychiatry 156 1999 158 159
89. J. Reich Use of high-dose olanzapine in refractory psychosis Am J Psychiatry 156 1999 661
90. S.W. Heimann High-dose olanzapine in an adolescent J Am Acad Child Adolesc Psychiatry 38 1999 496 497
91. S. Kapur, R.B. Zipursky, and G. Remington 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation Am J Psychiatry 155 1998 921 928
92. S. Kumra, L.K. Jacobsen, and M. Lenane Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents J Am Acad Child Adolesc Psychiatry 37 1998 377 385
93. S. Marder, and R. Meibach Risperidone in the treatment of schizophrenia Am J Psychiatry 151 1994 825 835
94. G. Chouinard, B. Jones, and G. Remington A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients J Clin Psychopharmacol 13 1993 25 40
95. D.A. Wirshing, B.D. Marshall, and M.F. Green Risperidone in treatment-refractory schizophrenia Am J Psychiatry 156 1999 1374 1379
96. S.W. Flynn, G.W. MacEwan, and S. Altman An open comparison of clozapine and risperidone in treatment-resistant schizophrenia Pharmacopsychiatry 31 1 1998 25 29
97. G. Bondolfi, H. Dufour, and M. Patris Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group Am J Psychiatry 155 4 1998 499 504
98. A. Breier, and P.H. Berg The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome Soc Biol Psychiatry 46 1999 361 364
99. D.L. Kleinberg, J.M. Davis, and R. de Coster Prolactin level and adverse events in patients treated with risperidone J Clin Psychopharmacol 19 1999 57 61
100. L.A. Arvanitis, B.G. Miller for the Seroquel Trial 13 Study Group Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo Biol Psychiatry 42 1997 233 246
101. J.G. Small, S.R. Hirsch, L.A. Arvanitis for the Seroquel Study Group Quetiapine in patients with schizophrenia Arch Gen Psychiatry 54 1997 549 557
102. J. Peuskens, and C.G. Link A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia Acta Psychiatr Scand 96 4 1997 265 273
103. E. Sacchetti, A. Panariello, and C. Regini Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial Schizophr Res 69 2004 325 331
104. J.M. Pierre, D.A. Wirshing, and W.C. Wirshing High-dose quetiapine in treatment refractory schizophrenia Schizophr Res 73 2-3 2005 373 375
105. G.M. Simpson, I.D. Glick, and P.J. Weiden Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill patients with schizophrenia or schizoaffective disorder Am J Psychiatry 161 10 2004 1837 1847
106. P.E. Keck Jr, K.R. Reeves, E.P. Harrington for the Ziprasidone Study Group Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies J Clin Psychopharmacol 21 1 2001 27 35
107. D.G. Daniel, D.L. Zimbroff, and S.G. Potkin Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group Neuropsychopharmacology 20 5 1999 491 505
108. D.C. Goff, T. Posever, and L. Herz An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder Clin Psychopharmacol 18 4 1998 296 304
109. D.B. Allison, J.L. Mentore, and M. Heo Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 11 1999 1686 1696
110. D.E. Addington, C. Pantelis, and M. Dineen Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial J Clin Psychiatry 65 12 2004 1624 1633
111. M.J. Labellarte, J.E. Crosson, and M.A. Riddle The relevance of prolonged QTc measurement to pediatric psychopharmacology J Am Acad Child Adolesc Psychiatry 42 6 2003 642 650
112. F.R. Sallee, R. Kurlan, and C.G. Goetz Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study J Am Acad Child Adolesc Psychiatry 39 3 2000 292 299
113. J. Blair, L. Scahill, and M. State Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study J Am Acad Child Adolesc Psychiatry 44 1 2005 73 79
114. W.O. Levy, N.R. Robichaux-Keene, and C. Nunez No significant QTc interval changes with high-dose ziprasidone: a case series J Psychiatr Pract 10 4 2004 227 232
115. L. Scahill, J. Blair, and J.F. Leckman Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone J Psychopharmacol 19 2 2005 205 206
116. S.G. Potkin, A.R. Saha, and M.J. Kujawa Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder Arch Gen Psychiatry 60 7 2003 681 690
117. R.D. McQuade, E. Stock, and R. Marcus A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study J Clin Psychiatry 65 Suppl 18 2004 47 56
118. J.M. Kane, W.H. Carson, and A.R. Saha Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder J Clin Psychiatry 63 9 2002 763 771
119. J. Biederman, M.A. McDonnell, and J. Wozniak Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review CNS Spectr 10 2 2005 141 148
120. J.M. Kane, E.J. Barrett, and D.E. Casey Metabolic effects of treatment with atypical antipsychotics J Clin Psychiatry 65 11 2004 1447 1455
121. C.U. Correll, and A.K. Malholtra Pharmacogenetics of antipsychotic- induced weight gain Psychopharmacol 174 4 2004 477 489
122. Y. Bloch, O. Vardi, and S. Mendlovic Hyperglycemia from olanzapine treatment in adolescents J Child Adolesc Psychopharmacol 13 1 2003 97 102
123. G. Ratzoni, D. Gothelf, and A. Brand-Gothelf Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study J Am Acad Child Adolesc Psychiatry 41 3 2002 337 343
124. D.A. Wirshing, W.C. Wishing, and L. Kysar Novel antipsychotics: comparison of weight gain liabilities J Clin Psychiatry 60 1999 358 363
125. D.C. Henderson, E. Cagliero, and C. Gray Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five year naturalistic study Am J Psychiatry 157 6 2000 975 981
126. R. Leadbetter, M. Shutty, and D. Pavalonis Clozapine-induced weight gain: prevalence and clinical relevance Am J Psychiatry 149 1992 68 72
127. D.D. Miller Review and management of clozapine side effects J Clin Psychiatry 61 Suppl 8 2000 14 17
128. R.R. Conley, and H.Y. Meltzer Adverse events related to olanzapine J Clin Psychiatry 61 Suppl 8 2000 26 29 [discussion: 30]
129. Physicians' desk reference 2000 Medical Economics Data Production Co Montvale (NY)
130. S.K. Ober, R. Hudak, and A. Rusterholtz Hyperglycemia and olanzapine [letter] Am J Psychiatry 165 1999 970
131. D.A. Wirshing, B.J. Spellberg, and S.M. Erhart Novel antipsychotics and new onset diabetes Biol Psychiatry 44 1998 778 783
132. J.P. Lindenmayer, and R. Patel Olanzapine-induced ketoacidosis with diabetes mellitus [letter] Am J Psychiatry 156 1999 1471 1472
133. L.E. Goldstein, J. Sporn, and S. Brown New onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment Psychosomatics 40 1999 438 443
134. S.M. Grundy Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome Am J Cardiol 81 4A 1998 18B 25B
135. B.B. Sheitman, P.M. Bird, and W. Binz Olanzapine-induced elevation of plasma triglyceride levels Am J Psychiatry 156 9 1999 1471 1472
136. O.M. Wolkowitz Rational polypharmacy in schizophrenia Ann Clin Psychiatry 5 1993 79 90
137. S.M. Stahl, and M.M. Grady A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation Curr Med Chem 11 3 2004 313 327
138. J.G. Small, J.J. Kellams, and V. Milstein A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients Am J Psychiatry 132 1975 1315 1317
139. G.A. Growe, J.W. Crayton, and D. Klass Lithium in chronic schizophrenia Am J Psychiatry 136 1979 454 455
140. J.S. Carmen, L.B. Bigelow, and R.J. Wyatt Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients J Clin Psychiatry 42 1981 124 128
141. D.F. Levinson, C. Umapathy, and M. Musthaq Treatment of schizoaffective disorder and schizophrenia with mood symptoms Am J Psychiatry 156 1999 1138 1148
142. T. Terao, T. Oga, and S. Nozaki Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized double-blind, placebo-controlled, cross-over study Acta Psychiatr Scand 92 1995 220 224
143. S.C. Schulz, P.A. Thompson, and M. Jacobs Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenia outpatients J Clin Psychiatry 60 1999 366 372
144. W.J. Cohen, and N.H. Cohen Lithium carbonate, haloperidol and irreversible brain damage JAMA 230 1974 1283 1287
145. F. Miller, and J. Menninger Lithium-neuroleptic neurotoxicity is dose-dependent J Psychopharmacol 7 1987 89 91
146. C. Simhandl, and K. Meszaros The use of carbamazepine in the treatment of schizophrenia and schizoaffective psychosis: a review J Psychiatry Neurosci 17 1992 1 14
147. D.E. Casey, D.G. Daniel, and A.A. Wasseff Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia Neuropsychopharmacology 28 1 2003 182 192
148. L. Citrome, D.E. Casey, and D.G. Daniel Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone Psychiatr Serv 55 3 2004 290 294
149. J.R. Calabrese, S. Trisha, and B.I. Charles A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder J Clin Psychiatry 61 11 2000 841 850
150. J. Tiihonen, T. Hallikainen, and O.P. Ryynanen Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial Biol Psychiatry 54 11 2003 1241 1248
151. I. Kremer, A. Vass, and I. Gorelik Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia Biol Psychiatry 56 6 2004 441 446
152. M. Duchowny, J.M. Pellock, and W.D. Graf A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children Neurology 46 1999 240 242
153. M. Duchowny, J.M. Pellock, and W.D. Graf A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children Neurology 53 1999 1724 1731
154. S.M. Dursun, D. McIntosh, and H. Milliken Clozapine plus lamotrigine in treatment-resistant schizophrenia Arch Gen Psychiatry 56 10 1999 950
155. J.T. Gilman, M.S. Duchowny, and J.A. Messenheimer Long-term tolerability of lamotrigine (Lamictal) in pediatric patients Ann Neurol Suppl 1 2001 S92
156. A. Anand, D.S. Charney, and D.A. Oren Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists Arch Gen Psychiatry 57 3 2000 270 276
157. T.A. Glauser Expanding first-line therapy options for children with partial seizures Neurology 55 3 2000 S30 S37
158. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am J Psychiatry 158 9 2001 1367 1377
159. D.C. Goff, and A.E. Evins Negative symptoms in schizophrenia- neurobiological models and treatment response Harv Rev Psychiatry 6 2 1998 59 77
160. O. Lingjaerde, E. Engstrand, and P. Ellingsen Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: a double-blind clinical trial Current Therapeutic Research 26 1979 505 512
161. O.M. Wolkowitz, N. Turetsky, and V.I. Reus Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia Psychopharmacol Bull 28 3 1992 291 295
162. G.W. Christison, D.H. Kirch, and R.J. Wyatt When symptoms persist: choosing among alternative somatic treatments for schizophrenia Schizophr Bull 17 2 1991 217 245
163. R.O. Friedel The combined use of neuroleptics and ECT in drug resistant schizophrenic patients Psychopharmacol Bull 22 3 1986 928 930
164. E. Pappadopulos, J.C. Macintyre II, and M.L. Crimson Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), Part II J Am Acad Child Adolesc Psychiatry 42 2 2003 145 161
165. A.E. Anil Yagcioglu, B.B. Kivircik Akdede, and T.I. Turgut A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety J Clin Psychiatry 66 1 2005 63 72